RNXT News & Events

RenovoRx announced continued commercial progress, with 12 U.S. cancer centers now utilizing the RenovoCath device. These 12 centers are in addition to those centers currently using RenovoCath as part of RenovoRx's ongoing Phase III trial. A total of 33 centers have requested access to RenovoCath, tripling the potential number of near-term commercial centers in RenovoRx's sales pipeline since the first quarter of 2025. The growing adoption reflects increasing clinical demand for RenovoCath as it becomes integrated into overall cancer treatment paradigms and sets the stage for Company revenue expansion in 2026.

RenovoRx announced that a clinical data abstract submission by cancer experts at Moffitt Cancer Center to the 2026 Society of Interventional Radiology, SIR, Annual Scientific Meeting has been accepted. The abstract, titled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer," was submitted by a multidisciplinary team of cancer experts, including Dr. Mustafa Al-Roubaie, an Interventional Radiologist at Moffitt Cancer Center and member of RenovoRx's Medical Advisory Board. The abstract explores the hypothesis, based on a review of metabolic response observations, that local, targeted intra-arterial delivery of chemotherapy using RenovoRx's patented TAMP therapy platform may help address the poor vascularity commonly associated with locally advanced pancreatic cancer. The abstract data further evaluates the potential role of metabolic imaging in evaluating therapeutic activity following targeted intra-arterial treatment in patients with refractory disease.

RenovoRx announced the formation of a RenovoCath Medical Advisory Board, MAB, to support its clinical and strategic initiatives. "The formation of the MAB marks an exciting milestone for RenovoRx, and we're honored to have such respected interventional radiology experts supporting advancement of the RenovoCath device," said Ramtin Agah, MD, RenovoRx's Chairman and Chief Medical Officer. "Their collective expertise will help guide real-world evidence generation as we advance our novel approach to localized, targeted drug delivery, aiming to improve outcomes for patients diagnosed with difficult-to-treat cancers."

RenovoRx announces the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Voll brings more than three decades of financial leadership experience to RenovoRx. He has served as Chief Financial Officer for multiple publicly traded technology companies .